Effect of Septal Ablation on Myocardial Relaxation and Left Atrial Pressure in Hypertrophic Cardiomyopathy

Size: px
Start display at page:

Download "Effect of Septal Ablation on Myocardial Relaxation and Left Atrial Pressure in Hypertrophic Cardiomyopathy"

Transcription

1 JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 5, BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN /08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: /j.jcin Effect of Septal Ablation on Myocardial Relaxation and Left Atrial Pressure in Hypertrophic Cardiomyopathy An Invasive Hemodynamic Study Paul Sorajja, MD, Rick A. Nishimura, MD, Steve R. Ommen, MD, Charanjit S. Rihal, MD, Bernard J. Gersh, MB, CHB, DPHIL, David R. Holmes, JR, MD Rochester, Minnesota Objectives The objective of this study was to examine the effects of septal ablation on diastolic function with the use of invasive hemodynamics. Background Septal ablation is an alternative therapy for patients with obstructive hypertrophic cardiomyopathy (HCM). However, its beneficial effect on diastolic function, by relieving the systolic contraction load, may be countered by adverse effects from the infarction on left ventricular mechanics. Methods Using high-fidelity, micromanometer-tipped catheters, we examined 40 HCM patients by taking direct measurements of the left ventricular outflow tract (LVOT) gradient, time constant of myocardial relaxation (tau), and left atrial pressure (LAP) before and after septal ablation. Results Although there was an overall reduction in LVOT gradient, septal ablation resulted in variable changes in myocardial relaxation and left atrial pressure. In 20 patients (50%), LAP increased. The magnitude of LVOT gradient reduction directly correlated with the effects of septal ablation on LAP (R 0.58; p ). Those patients with a greater decrease in the LVOT gradient had better improvement in direct LAP. Furthermore, those patients with a larger decrease in left ventricular outflow tract gradient had a beneficial enhancement of ventricular relaxation, as measured by tau (R 0.43; p 0.006). Thus, the beneficial enhancement of relaxation was directly related to improvement in LAP (R 0.75; p ). Conclusions Septal ablation results in variable effects on left ventricular filling pressure, which are dependent upon the magnitude of reduction in the LVOT gradient. These effects are mediated in part by effects of ablation on myocardial relaxation. These findings shed insight into the pathophysiologic effects of septal reduction therapy in patients with HCM. (J Am Coll Cardiol Intv 2008;1: ) 2008 by the American College of Cardiology Foundation From the Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota. Michael A. Kutcher, MD, FACC, served as Guest Editor for this paper. Manuscript received March 27, 2008; revised manuscript received July 8, 2008, accepted July 11, 2008.

2 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 1, NO. 5, Diastolic dysfunction is a prominent, complex phenomenon in patients with hypertrophic cardiomyopathy (HCM) that arises from an interplay of multiple interrelated factors. Ventricular relaxation plays a major role in diastolic filling and is dependent upon myocardial nonuniformity, perturbations in sarcomere inactivation, and altered loading conditions (1 4). Each of these components can be exacerbated by obstruction of the left ventricular outflow tract (LVOT), which leads to symptoms of heart failure and, in some studies, impaired survival (1 5). Likewise, as a therapeutic target, alleviation of LVOT obstruction could alter diastolic function in patients with HCM. However, few studies have directly examined the effect of septal reduction on myocardial relaxation and overall diastolic function of the left ventricle (6 8). Percutaneous septal ablation is an alternative therapy that has been shown to relieve LVOT obstruction in patients with HCMs, leading to significant improvement in both symptoms and objective measures of functional capacity (9 12). Nonetheless, despite its early success, there has been concern regarding the consequences of induction of a myocardial infarction in patients with HCM (13,14). Infarction of myocardium may exacerbate diastolic dysfunction as the result of an increase in myocardial stiffness as well as enhancement of ventricular nonuniformity. These detrimental effects may be of particular importance in patients with HCM who have hypertrophied noncompliant ventricles and are inherently predisposed to nonuniformity of both contraction and relaxation due to abnormal myofibril structure and function. Conversely, improvement in left ventricular filling pressures might occur if a large systolic contraction load is the predominant etiology for diastolic dysfunction and can be reduced by septal ablation. Accordingly, the objectives of the present study were to examine the effects of septal ablation on diastolic function in patients with HCM using invasive hemodynamics. Methods Study population. The Institutional Review Board approved this study. All participants provided informed consent. The study population consisted of 48 patients with obstructive HCM (LVOT gradient either 40 mm Hg at rest and/or 50 mm Hg during provocation) and normal sinus rhythm who presented to the Mayo Cardiac Catheterization Laboratory for septal ablation. Patients who had undergone a previous surgical myectomy, were diagnosed with moderate or greater aortic valvular disease, had significant intrinsic mitral disease, had left ventricular ejection fraction 50%, had coronary artery stenosis 30%, or had pacemaker dependency (before or after septal ablation) were not included. The diagnosis of HCM was based on typical clinical features with ventricular myocardial hypertrophy occurring in the absence of any other cardiac or systemic disease that could have been responsible for the hypertrophy (15,16). The magnitude of myocardial hypertrophy was assessed with M-mode and 2-dimensional transthoracic echocardiography with the use of standard techniques. Doppler echocardiography was used to ascertain the peak LVOT gradient (17). Mitral regurgitation was graded semiquantitatively with the use of Doppler echocardiography and color-flow imaging (grade I, mild; grade II, moderate; grade III, moderate-severe; grade IV, severe) (18). Hemodynamic evaluation. Before receiving septal ablation, each patient underwent a comprehensive hemodynamic evaluation with cardiac catheterization completed under conscious sedation in the fasting state. Transeptal puncture with placement of an 8-F Mullins sheath was performed for direct measurement of left atrial pressure (LAP) and left ventricular (LV) pressure. Simultaneous ascending aortic pressures with 6-F guide catheters were obtained via retrograde femoral access. Calibrated, high-fidelity, micromanometer-tipped catheters (Millar Instruments, Houston, Texas) were placed Abbreviations and Acronyms EDP end-diastolic pressure HCM hypertrophic cardiomyopathy LAP left atrial pressure LV left ventricle LVOT left ventricular outflow tract tau time constant of myocardial relaxation into the cardiac chambers. Rapid acquisition (5-ms intervals) digital records were obtained from 3 to 5 end-expiratory cardiac cycles (19). The following LV variables were measured: minimum diastolic pressure, LV end-diastolic pressure (EDP), mean LV diastolic pressure (measured during LV diastolic filling period), LV pre-a pressure, and the rate of increase (i.e., positive) and decrease (i.e., negative) in LV pressure (dp/dt) (19). From the left atrium, the following variables were measured: mean LAP, peak A wave pressure, peak V wave pressure, and V wave height. V wave height was defined as the pressure difference between the peak V wave and the nadir of the x descent in the left atrial pressure tracing (Fig. 1) (19). The time constant of myocardial relaxation (tau) was calculated by use of a zero asymptote method as described by Weiss et al. (20). As described previously, tau is defined as the negative inverse of the slope of the natural logarithm of pressure versus time during the isovolumic relaxation period. After a period of stabilization after septal ablation ( 15 min), this hemodynamic evaluation was repeated with the same methodology. Baseline cardiac medications were continued unchanged throughout the study. No intravenous or oral fluid administration was performed during the procedure apart from that required to deliver intravenous sedatives and analgesics. Septal ablation procedure. Septal ablation was performed in all patients with the use of previously described techniques

3 554 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 1, NO. 5, 2008 variable distributions were normally distributed, and a Wilcoxon rank sum or Mann-Whitney U test otherwise. Paired t tests or Wilcoxon rank sum test was used for within-group comparisons; unpaired t tests or Mann- Whitney U test was used for between-group comparisons. Continuous variables are reported with one standard deviation. Statistical significance was set at p Results Figure 1. Method for Pressure Recording Analysis Left atrium (LA), left ventricle (LV), and ascending aorta (Ao) demonstrating the hemodynamic variables used for characterization of diastolic function. (a) Minimum LV pressure; (b) LV pre-a pressure; (c) end-diastolic pressure, LV end-diastolic pressure; (d) LV diastolic filling period; (e) LA peak A wave pressure; (f) V wave height; (g) LA peak V wave pressure; (h) isovolumic relaxation period. (21,22). In brief, an oversized, over-the-wire angioplasty balloon was placed in the septal perforator artery from a left coronary guide catheter using standard methods. After balloon inflation, angiographic and echocardiographic contrast was injected through the balloon catheter to identify the perfusion bed of the septal perforator. After delineation of the targeted myocardium with contrast, 1 to 2 ml of desiccated ethanol was infused over the course of 3 min to 5 min followed by a normal saline flush. For patients with 50% reduction in either the resting or provoked LVOT gradient, other septal arteries were targeted and treated in similar fashion. As a precaution against the development of atrioventricular block, all patients underwent temporary pacemaker placement during the procedure. Hemodynamic evaluations were completed in each patient during normal sinus rhythm. Data analysis. To facilitate comparisons of hemodynamic variables before and after septal ablation, only patients who remained in sinus rhythm were examined. Eight patients (17%) who underwent baseline evaluation were not further analyzed because of the need for continuous pacing after septal ablation. Significant resting obstruction was defined as an LVOT gradient at rest of 40 mm Hg. Simple regression analyses were performed with Statview 4.0 (SAS Institute, Cary, North Carolina). Comparisons of continuous variables were made with a 2-sample t test when the Patient population. Mean age of the study population was years (Table 1). Eight patients had a history of atrial fibrillation but were in normal sinus rhythm during the study. The baseline LVOT gradient was either 40 mm Hg at rest (n 27) or 50 mm Hg with provocation in all patients. Mean LAP at baseline was mm Hg, with 33 patients (83%) having LAP 10 mm Hg. The baseline LAP (R 0.49; p 0.001), peak V wave (R 0.57; p ), and V wave height (R 0.57; p ) all were related to the severity of the LVOT gradient. The median dose of ethanol administered was ml. The LVOT gradient reduction and left atrial pressure. Septal ablation significantly reduced the resting LVOT gradient ( mm Hg to mm Hg; p ) (Table 2). For the 13 patients with significant LVOT gradients who presented only with provocation, ablation Table 1. Baseline Clinical Variables Age, yrs Male gender, n (%) 25 (63) NYHA functional class III, n (%) 39 (98) CCS class III, n (%) 15 (38) Presyncope or syncope, n (%) 17 (43) Family history of HCM, n (%) 9 (23) Asymmetric pattern of hypertrophy, n (%) 25 (63) Concentric pattern of hypertrophy, n (%) 15 (37) Maximum ventricular wall thickness, mm Interventricular septum, mm Posterior wall, mm End-diastolic diameter, mm End-systolic diameter, mm Left atrial volume index, ml/m Left ventricular ejection fraction, % 72 5 History of atrial fibrillation, n (%) 8 (20) Internal cardioverter-defibrillator, n (%) 1 (3) Medications, n (%) Beta-receptor antagonist 26 (65) Calcium-channel blocker 15 (37) Disopyramide 2 (5) ACE inhibitor or ARB 4 (10) Amiodarone 5 (13) ACE angiotensin-converting enzyme; ARB angiotensin-receptor blocker; CCS Canadian Cardiac Society; HCM hypertrophic cardiomyopathy; NYHA New York Heart Association.

4 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 1, NO. 5, Table 2. Baseline and Post-Procedural Invasive Hemodynamic Data Variable Baseline Post-Procedural p Value Systolic blood pressure, mm Hg Diastolic blood pressure, mm Hg Heart rate, beats/min Left atrial pressure, mm Hg LV pre-a pressure, mm Hg Peak A wave pressure, mm Hg Peak V wave pressure, mm Hg V wave height, mm Hg Minimum LV pressure, mm Hg Mean LV diastolic pressure, mm Hg LV end-diastolic pressure, mm Hg Peak positive dp/dt 1, , tau (ms) Invasive LVOT gradient, mm Hg Resting Post-PVC dp/dt rate of increase and decrease in left ventricular pressure; LV left ventricular; LVOT left ventricular outflow tract; PVC premature ventricular contraction; tau time constant of myocardial relaxation. reduced the provoked gradient from mm Hg to mm Hg (p ). The mean reduction in the resting LVOT gradient was %, including 32 patients who had a reduction of 80%. Although reduction in the LVOT gradient occurred in the majority of patients, the effects of septal ablation on LAP were variable with a broad range of effect ( 12 mm Hg to 18 mm Hg) (Fig. 2). There was no significant change in LAP in the overall population. The LAP increased after septal ablation in 20 patients (50%). In the remaining patients, there was either no change (n 4, or 10%) or a decrease in LAP (n 16, or 40%). The effect of septal ablation on LAP was directly related to the magnitude of reduction in LVOT gradient (R 0.58; p ). The relation of LVOT gradient reduction and LAP change remained evident (R 0.52; p 0.006) in analyses that excluded patients who had significant resting LVOT obstruction. Myocardial relaxation. Mean tau at baseline was ms, with 38 patients (95%) having tau 35 ms. After septal ablation, there was a mild prolongation of tau to ms in the overall study population (p 0.16 vs. baseline). Septal ablation resulted in an increase in tau in 22 patients (55%), and either no change (n 2, or 5%) or a decrease (n 16, or 40%) in tau in the remaining patients. Similarly, minimum left ventricular pressure increased in 20 patients (50%), and remained either unchanged (n 2, or 5%) or decreased (n 18, or 45%) after septal ablation in the remaining patients. The magnitude of reduction in the LVOT gradient was directly related to the effect of septal ablation on myocardial relaxation, as gauged by change in tau (R 0.43; p 0.006) and change in minimum left ventricular pressure (R 0.56; p ) (Figs. 3 and 4). Furthermore, the effect of septal ablation on myocardial relaxation was directly related to the change in LAP (Fig. 3). The regression coefficient for change in tau versus change in LAP was R 0.75 (p ). Overall, both worsening of myocardial relaxation (measured by tau) and an increase in LAP occurred in 18 patients (45%). Predictors of Change in LAP With Septal Ablation Baseline LVOT gradient, myocardial relaxation indices (tau and minimum left ventricular pressure), and ventricular filling pressures (LAP, mean diastolic pressure, LV pre-a pressure, EDP) were related to change in LAP (Table 3). The greater the LVOT gradient at rest, the greater the ventricular filling pressure, and a greater change in LAP. In addition, for patients whose baseline LAP was 20 mm Hg, the LVOT gradient decreased mm Hg and LAP change was mm Hg. Conversely, for patients whose baseline LAP was 20 mm Hg, the LVOT gradient decreased mm Hg (p vs. baseline LAP 20 mm Hg) and LAP change was mm Hg (p vs. baseline LAP 20 mm Hg). The change in LAP was not related to the pre-procedural severity of mitral regurgitation (p 0.45 for LAP change, grade I/II vs. grade III/IV). Patients with high LVOT gradients had a decrease in LAP irrespective of the severity of mitral regurgitation (Fig. 5). Variables of myocardial hypertrophy, ventricular cavity size, and LA size were not predictive of the change in LAP after septal ablation.

5 556 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 1, NO. 5, 2008 Discussion Figure 2. Effect of Septal Ablation on the LVOT Gradient (A) Change in left ventricular outflow tract (LVOT) gradient with septal ablation, (B) change in left atrial pressure (LAP) with septal ablation, and (C) the relation between change in LVOT gradient and change in LAP with septal ablation. Septal ablation resulted in variable effects on left atrial pressure, which correlated with the extent of LVOT gradient reduction. Closed circles patients with resting LVOT gradients of 40 mm Hg; open circles patients with resting LVOT gradients of 40 mm Hg. The principal findings of this study are as follows: 1) The effects of septal ablation on LAP are variable; 2) these effects on LAP are directly related to the magnitude of LVOT gradient reduction; 3) changes in LAP from septal ablation are mediated, at least in part, by the effects of ablation on myocardial relaxation; and 4) improvement in LAP from septal ablation may occur independently of the baseline severity of mitral regurgitation. Diastolic dysfunction is a complex phenomenon that has been described in a variety of cardiac disease states, but its presence in HCM is associated with a complex interplay of multiple interrelated events that are unique to these patients. These processes include abnormal myocardial stiffness due to myocardial hypertrophy and interstitial fibrosis, myocardial ischemia from microvascular disease and abnormal coronary flow reserve, viscoelastic forces on the myocardium, concomitant mitral regurgitation, and prolongation of ventricular relaxation. Obstruction of the LVOT may exacerbate diastolic dysfunction by increasing myocardial ischemia, creating severe secondary mitral regurgitation, and adversely affecting ventricular relaxation (1 4). Current therapies for septal reduction, namely, surgical myectomy and percutaneous septal ethanol ablation, are highly efficacious at relieving LVOT obstruction and related mitral regurgitation. Less clear, however, is the impact of these therapies on diastolic function. In particular, septal ablation, which is being used increasingly, relies on induction of myocardial infarction for its efficacy (9 12). By simultaneously altering ventricular load and increasing nonuniformity, septal ablation potentially affects several pathophysiologic processes that contribute to diastolic dysfunction in opposite ways (4). In patients with HCM who undergo surgical or percutaneous septal reduction therapy, relief of the systolic contraction load (i.e., LVOT obstruction), may beneficially affect LV filling pressures. Although the effects of septal ablation on LAP were highly variable, the present investigation demonstrates that the effects on LAP are directly related to the baseline severity and extent of the reduction in the LVOT gradient. The relation between LVOT gradient reduction and LAP also remained evident in analyses that excluded patients without significant resting gradients. These data therefore demonstrate that the magnitude and relief of systolic contraction load directly impact the net effects of septal ablation on diastolic function. Successful reduction of high LVOT gradients with septal ablation results in a net lusitropic effect. Conversely, septal ablation that results in relatively small- or no-decreases in systolic contraction load either have no benefit or may acutely worsen diastolic dysfunction. Variable effects on myocardial relaxation from septal ablation also help to explain the observed different effects on

6 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 1, NO. 5, Figure 3. Effect of LVOT Gradient Reduction on Myocardial Relaxation and Left Atrial Pressure The effect of septal ablation on minimum left ventricular pressure (A) and the time constant of mycardial relaxation (tau) (B) varied according to the extent of left ventricular outflow tract (LVOT) gradient reduction. Furthermore, the effects on minimum left ventricular pressure and tau were directly related to the changes in left atrial pressure from septal ablation (C and D). Closed circles patients with resting LVOT gradients of 40 mm Hg; open circles patients with resting LVOT gradients of 40 mm Hg. ventricular filling pressure. Approximately 50% of patients had acute worsening of myocardial relaxation and LAP. In some patients undergoing septal ablation, enhancement of ventricular nonuniformity by myocardial infarction therefore may overwhelm the beneficial effects on diastolic function afforded by relief of LVOT obstruction (23). Those patients with milder degrees of LVOT obstruction and diastolic dysfunction may be particularly sensitive to enhancement of ventricular nonuniformity by septal ablation, because an increase in LAP occurred more commonly in these patients. These observations suggest septal ablation may be relatively more advantageous in patients in whom there is severe LVOT obstruction and associated myocardial relaxation abnormalities that may be exacerbated by pathologic loading conditions. In those patients, septal ablation may have greater salutary effects on ventricular filling pressures. In patients with HCM, increased systolic contraction load from LVOT obstruction may alter myocardial relaxation through enhancement of regional asynchrony or nonuniformity, myocardial ischemia, and effects on fiber shortening and intracellular calcium ion handling (4,23). Dynamic mitral regurgitation also frequently accompanies obstructive HCM, and may lead to elevation in ventricular filling pressures. In few previous studies, both pharmacotherapy and surgical myectomy for LVOT obstruction have been associated with improved myocardial relaxation and decreases in ventricular filling pressure (24 26). In the present investigation, the extent of reduction in the systolic LVOT gradient correlated with changes in myocardial relaxation as assessed by tau and minimum LV pressure, which serves as a surrogate of ventricular diastolic suction. Moreover, the positive or negative changes in myocardial relaxation from septal ablation were directly related to the changes in LAP. Certainly, greater dynamic mitral regurgitation may be more common in those with relatively more severe LVOT obstruction. However, decreases in LAP were observed in one-third of the patients with mild or moderate mitral regurgitation, and LAP change was not different according to the baseline severity of mitral regurgitation. A 80% reduction in the LVOT gradient occurred in 80% of patients, suggesting that improvement of dynamic mitral regurgitation occurred in the vast majority of patients. Furthermore, the authors of previous studies (27 29) have demonstrated that greater severity of mitral regurgitation results in enhanced ventric-

7 558 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 1, NO. 5, 2008 Figure 4. Sample Hemodynamic Tracings From 4 Patients Before and After Septal Ablation (A) The patient was a 56-year-old woman with a marked increase in the left ventricular outflow tract gradient. After septal ablation, there were acute decreases in tau (the time constant of myocardial relaxation), minimum left ventricular pressure, and left atrial pressure. (B) Similarly, in this 62-year-old man with a left ventricular outflow tract gradient of 113 mm Hg, septal ablation resulted improvement in myocardial relaxation and left atrial pressure. (C and D) Two patients (a 71-year-old man and a 67-year-old man, respectively) who had relatively lower left ventricular outflow tract gradients. Septal ablation resulted in acute prolongation of tau and elevation in ventricular filling pressures in both of these patients. LAP left arterial pressure; LV-MIN minimum left ventricular diastolic pressure; other abbreviations as in Figure 1. ular relaxation (i.e., lower tau); therefore, relief of mitral regurgitation would not lead to lusitropic effects in the present study. In the study herein, the decrease in LAP correlated closely with a decrease in LV minimum diastolic pressure, supporting the contribution of changes in relaxation rather than mitral regurgitation. Thus, although relief of dynamic mitral regurgitation may lead to improvement in LAP, the high-fidelity measures of LV pressure decay in this study suggest that the effects of septal ablation on LAP are mediated, at least in part, by alterations in myocardial relaxation from relief of systolic contraction load. Ideal therapy for diastolic dysfunction in patients with obstructive HCM would relieve the burden of the LVOT gradient without affecting ventricular nonuniformity or exacerbating other components of diastolic function. Although there was a net salutary effect on diastolic function in some patients, persistent or enhanced ventricular nonuniformity from septal ablation may have obviated further decrement in LAP. Surgical myectomy is considered the gold standard for septal reduction therapy, and theoretically may have a less adverse effect on ventricular nonuniformity than septal ablation (13). Nonetheless, analogous to the present study, the clinical efficacy of surgical myectomy also has been found to be directly related to operative reduction in LVOT gradient and EDP (30). Furthermore, persistent ventricular nonuniformity has been proposed as a mechanism for continued impaired exercise capacity after surgical myectomy (31).

8 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 1, NO. 5, Table 3. Regression Coefficients for the Relation Between Baseline Variables and the Dependent Variable of Change in Left Atrial Pressure After Ablation Variable R p Value Study limitations. The acute nature of this hemodynamic study restricted the ability to examine the long-term consequences of change in diastolic function that resulted from septal ablation. Infarct-related remodeling occurs after ablation (32). As the result of the absence of a clinical indication for repeat catheterization, further characterization of diastolic function with invasive means in subsequent follow-up was not attempted. We did not pursue chronic studies by using echocardiography because the current noninvasive methods of examining diastolic function in patients with HCM are of limited accuracy (33). In addition, we did not believe it was ethical to perform invasive cardiac catheterization on these patients in follow-up. Thus, this investigation was limited to the acute setting. Second, because of the inherent difficulties in the echocardiographic quantification of dynamic mitral regurgitation because of obstructive HCM, such measures of mitral regurgitation were not undertaken. Third, variations in septal infarct size could contribute to the observed heterogeneity in the effects of septal ablation and quantitative measures of infarct size were not systematically performed. Finally, the present investigation examined diastolic function only in resting conditions and the effects of ablation on exercise-induced diastolic dysfunction remain unknown. Age Maximal left ventricular wall thickness Ventricular septal thickness Posterior wall thickness End-diastolic diameter End-systolic diameter Left atrial volume index Ejection fraction Resting gradient Provoked gradient (n 24) Heart rate Systolic blood pressure Diastolic blood pressure Peak positive dp/dt Volume ethanol injected LA peak A pressure LA peak V pressure LA V wave height Minimum left ventricular pressure Left ventricular pre-a pressure Mean left ventricular pressure Left ventricular end-diastolic pressure LA pressure Baseline tau dp/dt rate of increase and decrease in left ventricular pressure; LA left atrial; R regression coefficients. Figure 5. Change in Left Atrial Pressure and Myocardial Relaxation According to the Severity of LVOT Gradient and Baseline MR Only 2 patients had LVOT gradient 50 mm Hg and grade III or IV mitral regurgitation. However, as shown in (A), septal ablation led to decreases in left atrial pressure in patients with gradient 50 mm Hg independently of the severity of MR, whereas those patients with LVOT gradient 50 mm Hg more commonly had increases in left atrial pressure. *p and **p 0.03 for comparison versus LVOT gradient 50 mm Hg and grade I or II mitral regurgitation. Furthermore, as shown in (B), improvement in tau (the time constant of myocardial relaxation) was observed in patients with gradients 50 mm Hg independently of the severity of MR. However, prolongation of tau more frequently occurred in those patients with gradients 50 mm Hg. *p and **p 0.03 for comparisons versus LVOT gradient 50 mm Hg and grade I or II mitral regurgitation. All other comparisons were not statistically significant. LVOT left ventricular outflow tract; MR myocardial relaxation.

9 560 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 1, NO. 5, 2008 Conclusions By using high-fidelity invasive measurements, we have shown a variable effect of septal ablation on diastolic function in patients with HCM. There are several competing factors that determine the final effect on LAP, including the relief of contraction load, effect on ventricular relaxation, residual degree of mitral regurgitation, as well as the primary consequence of the myocardial infarction. These findings shed insight into the pathophysiological consequences of relief of LVOT obstruction in patients with HCM. Reprint requests and correspondence: Dr. Rick A. Nishimura, 200 1st Street SW, Rochester, Minnesota rick.nishimura@mayo.edu. REFERENCES 1. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287: Elliott PM, Brecker SJ, McKenna WJ. Diastolic dysfunction in hypertrophic cardiomyopathy. Eur Heart J 1998;19: Nishimura RA, Holmes DR Jr. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004;350: Brusaert DL, Rademakers RE, Sys SU. Triple control of myocardial relaxation: implications in cardiac disease. Circulation 1984;69: Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348: Nagueh SH, Lakkkis NM, Middleton KJ, et al. Changes in left ventricular diastolic function 6 mos after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 1999;99: Sitges M, Shiota T, Lever HM, et al. Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. Am J Cardiol 2003;91: Rovner A, Smith R, Greenberg NL, et al. Improvement in diastolic intraventricular pressure gradients in patients with HOCM after ethanol septal reduction. Am J Physiol Heart Circ Physiol 2003;285: H Faber L, Seggewiss H, Welge D, et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiogr 2004;5: Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic cardiomyopathy. J Am Coll Cardiol 2001;38: Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001;38: Firoozi S, Elliott PM, Sharma S, et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic cardiomyopathy. Eur Heart J 2002;23: Maron BJ, Dearani JA, Ommen SR, et al. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44: Hess OM, Sigwart U. New treatment strategies for hypertrophic obstructive cardiomyopathy. Alcohol ablation of the septum: the new gold standard? J Am Coll Cardiol 2004;44: Report of the World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996;93: Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol 1979;43: Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1992;19: Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16: Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures. A comparative simultaneous Doppler-catheterization study. Circulation 2000;102: Weiss JL, Frederiksen JW, Weisfeldt ML. Hemodynamic determinants of the time-course of fall in canine left ventricular pressure. J Clin Invest 1976;58: Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008;118: Valeti U, Nishimura RA, Holmes DR, et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2007;49: Aoyagy T, Iizuka M, Takahashi K, et al. Wall motion asynchrony prolongs time-constant of left ventricular relaxation. Am J Physiol 1989;257:H Matsubara H, Nakatani S, Nagata S, et al. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1995;26: Schoendube FA, Klues HG, Reith S, et al. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 1995;92: Bonow RO, Vitale DF, Maron BJ, et al. Regional left ventricular synchrony and impaired global left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. J Am Coll Cardiol 1987;9: Zile MR, Tomita M, Nakano K, et al. Effects of left ventricular volume overload produced by mitral regurgitation on diastolic function. Am J Physiol 1991;261:H Zile MR, Tomita M, Ishihara K, et al. Changes in diastolic function during development and correction of chronic LV volume overload produced by mitral regurgitation. Circulation 1993;87: Tsutsui H, Urabe Y, Mann DL, et al. Effects of chronic mitral regurgitation on diastolic function in isolated cardiocytes. Circ Res 1993;72: Diodati JG, Schenke WH, Waclawis MA, McIntosh CL, Cannon RO 3rd. Predictors of exercise benefit after operative relief of left ventricular outflow obstruction by the myotomy-myectomy procedure in hypertrophic cardiomyopathy. Am J Cardiol 1992;69: Mundhenke M, Schwartzkopff B, Stark P, Schulte HD, Strauer BE. Myocardial collagen type I and impaired left ventricular function under exercise in hypertrophic cardiomyopathy. Thorac Cardiovasc Surg 2002;50: Van Dockum WG, Beek AM, ten Cate FJ, et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2005;111: Geske J, Sorajja P, Nishimura RA, Ommen SR. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation 2007;116: Key Words: hypertrophic cardiomyopathy septal ablation diastole.

Medical Policy and and and and

Medical Policy and and and and ARBenefits Approval: 10/12/2011 Effective Date: 01/01/2012 Revision Date: Code(s): 93799, Unlisted cardiovascular service or procedure Medical Policy Title: Percutaneous Transluminal Septal Myocardial

More information

Variability of Left Ventricular Outflow Tract Gradient During Cardiac Catheterization in Patients With Hypertrophic Cardiomyopathy

Variability of Left Ventricular Outflow Tract Gradient During Cardiac Catheterization in Patients With Hypertrophic Cardiomyopathy JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 6, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.02.014 Variability

More information

Assessment of Left Ventricular Outflow Gradient

Assessment of Left Ventricular Outflow Gradient JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 6, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.01.026

More information

ORIGINAL PAPER. R. C. Steggerda & J. C. Balt & K. Damman & M. P. van den Berg & J. M. ten Berg

ORIGINAL PAPER. R. C. Steggerda & J. C. Balt & K. Damman & M. P. van den Berg & J. M. ten Berg Neth Heart J (2013) 21:504 509 DOI 10.1007/s12471-013-0453-4 ORIGINAL PAPER Predictors of outcome after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Special interest

More information

Case Presentation: A 58-yearold

Case Presentation: A 58-yearold CLINICIAN UPDATE Role of Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy Carey D. Kimmelstiel, MD; Barry J. Maron, MD Case Presentation: A 58-yearold diabetic man was referred for

More information

Index of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125

Index of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125 145 Index of subjects A accessory pathways 3 amiodarone 4, 5, 6, 23, 30, 97, 102 angina pectoris 4, 24, 1l0, 137, 139, 140 angulation, of cavity 73, 74 aorta aortic flow velocity 2 aortic insufficiency

More information

Journal of the American College of Cardiology Vol. 34, No. 4, by the American College of Cardiology ISSN /99/$20.

Journal of the American College of Cardiology Vol. 34, No. 4, by the American College of Cardiology ISSN /99/$20. Journal of the American College of Cardiology Vol. 34, No. 4, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00341-1 Changes

More information

HYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure. Paolo Spirito, Genoa, Italy

HYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure. Paolo Spirito, Genoa, Italy HYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure Paolo Spirito, Genoa, Italy Clinical Substrates for Heart Failure Symptoms in HCM Diastolic dysfunction Atrial fibrillation LV outflow obstruction Evolution

More information

Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert

Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert University of Groningen Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you

More information

Management of HOCM: Non-Surgical Options

Management of HOCM: Non-Surgical Options Management of HOCM: Non-Surgical Options Howard C. Herrmann, MD, FACC, MSCAI John Bryfogle Professor of Cardiovascular Medicine and Surgery Health System Director for Interventional Cardiology Director,

More information

The 2014 Mayo Approach to the Management of HCM and Non-Compaction

The 2014 Mayo Approach to the Management of HCM and Non-Compaction The 2014 Mayo Approach to the Management of HCM and Non-Compaction R A Nishimura MD MACC MACP Judd and Mary Morris Leighton Professor Mayo Clinic No disclosures or conflict of interest CP1288794-1 Let

More information

Hypertrophic Obstructive Cardiomyopathy

Hypertrophic Obstructive Cardiomyopathy The new england journal of medicine clinical practice Hypertrophic Obstructive Cardiomyopathy Rick A. Nishimura, M.D., and David R. Holmes, Jr., M.D. This Journal feature begins with a case vignette highlighting

More information

Alcohol Septal Abla-on: Is This Now First Line Treatment for Hypertrophic Obstruc-ve Cardiomyopathy (HOCM)?

Alcohol Septal Abla-on: Is This Now First Line Treatment for Hypertrophic Obstruc-ve Cardiomyopathy (HOCM)? Alcohol Septal Abla-on: Is This Now First Line Treatment for Hypertrophic Obstruc-ve Cardiomyopathy (HOCM)? Sarang Mangalmur+, MD Bryn Mawr Hospital, PA NCVH New Jersey 2015 Disclosures No relevant disclosures

More information

Interventional Imaging Cases

Interventional Imaging Cases Interventional Imaging Cases Steven A. Goldstein MD Professor of Medicine Georgetown University Medical Center MedStar Heart Institute Washington Hospital Center Tuesday, October 10, 2017 DISCLOSURE I

More information

Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy. CardioVascular Research Foundation

Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy. CardioVascular Research Foundation Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy Alcohol Septal Ablation (ASA) Nonsurgical technique for septal myocardial reduction Dramatic hemodynamic improvement Technically easy

More information

NON-INVASIVE TREATMENT OPTIONS IN HYPERTROPHIC CARDIOMYOPATHY

NON-INVASIVE TREATMENT OPTIONS IN HYPERTROPHIC CARDIOMYOPATHY NON-INVASIVE TREATMENT OPTIONS IN HYPERTROPHIC CARDIOMYOPATHY SGK, 2015 Christiane Gruner University Heart Center, Zurich Department of Cardiology NONINVASIVE TREATMENT OPTIONS: TOPICS 1. LVOT obstruction

More information

The Management of Hypertrophic Cardiomyopathy

The Management of Hypertrophic Cardiomyopathy The Management of Hypertrophic Cardiomyopathy Evidence and Uncertainties Banff 2013 3058464-0 Management of HCM Key Elements Screen 1 relatives for HCM Serial Echo Genetic testing Assess risk for and prevent

More information

Septal myotomy myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy

Septal myotomy myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy European Heart Journal (2002) 23, 1617 1624 doi:10.1053/euhj.2002.3285, available online at http://www.idealibrary.com on Septal myotomy myectomy and transcoronary septal alcohol ablation in hypertrophic

More information

University of Groningen. Alcohol septal ablation Liebregts, Max

University of Groningen. Alcohol septal ablation Liebregts, Max University of Groningen Alcohol septal ablation Liebregts, Max IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document

More information

Dynamic left ventricular outflow tract (LVOT) obstruction

Dynamic left ventricular outflow tract (LVOT) obstruction Arrhythmia/Electrophysiology Survival After Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy Paul Sorajja, MD; Steve R. Ommen, MD; David R. Holmes, Jr, MD; Joseph A. Dearani, MD; Charanjit

More information

Update on Evaluation and Nonsurgical Treatment Strategies for the Symptomatic Patient with HCM

Update on Evaluation and Nonsurgical Treatment Strategies for the Symptomatic Patient with HCM Update on Evaluation and Nonsurgical Treatment Strategies for the Symptomatic Patient with HCM Richard G. Bach, MD, FACC, FAHA Professor of Medicine Director, Hypertrophic Cardiomyopathy Center Washington

More information

marked increase in thickness of walls of heart in patient with HCM.

marked increase in thickness of walls of heart in patient with HCM. Surgical Management of Hypertrophic Obstructive Cardiomyopathy Hani K. Najm MD, Msc, FRCSC, FRCS (Glasg Glasg), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi

More information

Influence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy

Influence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy ORIGINAL ARTICLE 5 RAAS inhibitors should be avoided if possible in patients with obstructive HCM Influence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy Katrin Witzel,

More information

Left atrial function. Aliakbar Arvandi MD

Left atrial function. Aliakbar Arvandi MD In the clinic Left atrial function Abstract The left atrium (LA) is a left posterior cardiac chamber which is located adjacent to the esophagus. It is separated from the right atrium by the inter-atrial

More information

HYPERTROPHIC CARDIOMYOPATHY (HCM) PRESENTED AS UNSTABLE ANGINA COMPLICATED BY SERIOUS VENTRICULAR ARRHYTHMIAS CASE REPORT AND REVIEW LITERATURE

HYPERTROPHIC CARDIOMYOPATHY (HCM) PRESENTED AS UNSTABLE ANGINA COMPLICATED BY SERIOUS VENTRICULAR ARRHYTHMIAS CASE REPORT AND REVIEW LITERATURE HYPERTROPHIC CARDIOMYOPATHY (HCM) PRESENTED AS UNSTABLE ANGINA COMPLICATED BY SERIOUS VENTRICULAR ARRHYTHMIAS CASE REPORT AND REVIEW LITERATURE Lusyun Kumar Yadav * and Jin li Jun Department of Cardiology,

More information

How NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto

How NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto How NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto Introduction Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy,

More information

Diastolic dysfunction is a major contributor to the underlying. Imaging

Diastolic dysfunction is a major contributor to the underlying. Imaging Imaging Evaluation of Left Ventricular Filling Pressures by Doppler Echocardiography in Patients With Hypertrophic Cardiomyopathy Correlation With Direct Left Atrial Pressure Measurement at Cardiac Catheterization

More information

Steel vs Alcohol. Or Neither. Management of Hypertrophic Cardiomyopathy. Josh Doll, MD January 24, 2015

Steel vs Alcohol. Or Neither. Management of Hypertrophic Cardiomyopathy. Josh Doll, MD January 24, 2015 Steel vs Alcohol Or Neither Management of Hypertrophic Cardiomyopathy Josh Doll, MD January 24, 2015 47yo Male, Mr. L Severe progressive dyspnea on exertion and weight gain Previous avid Cross-Fit participant

More information

Managing Hypertrophic Cardiomyopathy with Imaging. Gisela C. Mueller University of Michigan Department of Radiology

Managing Hypertrophic Cardiomyopathy with Imaging. Gisela C. Mueller University of Michigan Department of Radiology Managing Hypertrophic Cardiomyopathy with Imaging Gisela C. Mueller University of Michigan Department of Radiology Disclosures Gadolinium contrast material for cardiac MRI Acronyms Afib CAD Atrial fibrillation

More information

Patients with hypertrophic cardiomyopathy (HCM) and an

Patients with hypertrophic cardiomyopathy (HCM) and an Role of Transcoronary Ablation of Septal Hypertrophy in Patients With Hypertrophic Cardiomyopathy, New York Heart Association Functional Class III or IV, and Outflow Obstruction Only Under Provocable Conditions

More information

Journal of the American College of Cardiology Vol. 49, No. 3, by the American College of Cardiology Foundation ISSN /07/$32.

Journal of the American College of Cardiology Vol. 49, No. 3, by the American College of Cardiology Foundation ISSN /07/$32. Journal of the American College of Cardiology Vol. 49, No. 3, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.08.055

More information

Hypertrophic Cardiomyopathy: Patient Management in 2018

Hypertrophic Cardiomyopathy: Patient Management in 2018 Hypertrophic Cardiomyopathy: Patient Management in 2018 Mackram F. Eleid, MD Giornate Cardiologeche Torinesi October 26, 2018 2018 MFMER slide-1 Disclosures No relevant financial relationships to disclose

More information

Endocardial Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy

Endocardial Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy Journal of the American College of Cardiology Vol. 57, No. 5, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.07.055

More information

Hypertrophic Cardiomyopathy Ud Din Shah, MD; DM; FICC; FESC; FACC

Hypertrophic Cardiomyopathy Ud Din Shah, MD; DM; FICC; FESC; FACC 3 Article 1 Physicians Academy January 2018 Hypertrophic Cardiomyopathy Mehraj Ud Din Shah, MD; DM; FICC; FESC; FACC Hypertrophic Cardiomyopathy (HCM) is a genetic disorder which causes clinically unexplained

More information

Aortic stenosis (AS) is common with the aging population.

Aortic stenosis (AS) is common with the aging population. New Insights Into the Progression of Aortic Stenosis Implications for Secondary Prevention Sanjeev Palta, MD; Anita M. Pai, MD; Kanwaljit S. Gill, MD; Ramdas G. Pai, MD Background The risk factors affecting

More information

An Integrated Approach to Study LV Diastolic Function

An Integrated Approach to Study LV Diastolic Function An Integrated Approach to Study LV Diastolic Function Assoc. Prof. Adriana Ilieşiu, FESC University of Medicine Carol Davila Bucharest, Romania LV Diastolic Dysfunction impaired relaxation (early diastole)

More information

The Management of HOCM: What are the Surgical Options

The Management of HOCM: What are the Surgical Options The Management of HOCM: What are the Surgical Options Konstadinos A Plestis, MD System Chief of Cardiac Thoracic and Vascular Surgery Main Line Health Care System Professor Sidney Kimmel Medical College

More information

*The first two authors contributed equally to this work

*The first two authors contributed equally to this work Original Research Hellenic J Cardiol 2014; 55: 132-138 Surgical Septal Myectomy for Hypertrophic Cardiomyopathy in Greece: A Single-Center Initial Experience Georgios K. Efthimiadis 1*, Antonis Pitsis

More information

Advanced imaging of the left atrium - strain, CT, 3D, MRI -

Advanced imaging of the left atrium - strain, CT, 3D, MRI - Advanced imaging of the left atrium - strain, CT, 3D, MRI - Monica Rosca, MD Carol Davila University of Medicine and Pharmacy, Bucharest, Romania Declaration of interest: I have nothing to declare Case

More information

Evalua&on)of)Le-)Ventricular)Diastolic) Dysfunc&on)by)Echocardiography:) Role)of)Ejec&on)Frac&on)

Evalua&on)of)Le-)Ventricular)Diastolic) Dysfunc&on)by)Echocardiography:) Role)of)Ejec&on)Frac&on) Evalua&on)of)Le-)Ventricular)Diastolic) Dysfunc&on)by)Echocardiography:) Role)of)Ejec&on)Frac&on) N.Koutsogiannis) Department)of)Cardiology) University)Hospital)of)Patras)! I have no conflicts of interest

More information

Constrictive Pericarditis in the Modern Era

Constrictive Pericarditis in the Modern Era Journal of the American College of Cardiology Vol. 51, No. 3, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.09.039

More information

Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy 019-CardioCase:019-CardioCase 4/16/07 1:39 PM Page 19 Hypertrophic Cardiomyopathy Abdullah Alshehri, MD; and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Presley s check-up Presley, 37, discovered

More information

Journal of the American College of Cardiology Vol. 44, No. 9, by the American College of Cardiology Foundation ISSN /04/$30.

Journal of the American College of Cardiology Vol. 44, No. 9, by the American College of Cardiology Foundation ISSN /04/$30. Journal of the American College of Cardiology Vol. 44, 9, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.04.062 Relation

More information

Septal Myectomy, Papillary Muscle Resection, and Mitral Valve Replacement for Hypertrophic Obstructive Cardiomyopathy: A Case Report

Septal Myectomy, Papillary Muscle Resection, and Mitral Valve Replacement for Hypertrophic Obstructive Cardiomyopathy: A Case Report Case Report Septal Myectomy, Papillary Muscle Resection, and Mitral Valve Replacement for Hypertrophic Obstructive Cardiomyopathy: A Case Report Junichiro Takahashi, MD, 1 Yutaka Wakamatsu, MD, 1 Jun Okude,

More information

Jong-Won Ha*, Jeong-Ah Ahn, Jae-Yun Moon, Hye-Sun Suh, Seok-Min Kang, Se-Joong Rim, Yangsoo Jang, Namsik Chung, Won-Heum Shim, Seung-Yun Cho

Jong-Won Ha*, Jeong-Ah Ahn, Jae-Yun Moon, Hye-Sun Suh, Seok-Min Kang, Se-Joong Rim, Yangsoo Jang, Namsik Chung, Won-Heum Shim, Seung-Yun Cho Eur J Echocardiography (2006) 7, 16e21 CLINICAL/ORIGINAL PAPERS Triphasic mitral inflow velocity with mid-diastolic flow: The presence of mid-diastolic mitral annular velocity indicates advanced diastolic

More information

Strain/Untwisting/Diastolic Suction

Strain/Untwisting/Diastolic Suction What Is Diastole and How to Assess It? Strain/Untwisting/Diastolic Suction James D. Thomas, M.D., F.A.C.C. Cardiovascular Imaging Center Department of Cardiology Cleveland Clinic Foundation Cleveland,

More information

HOCM: Alcohol ablation or LVOT Surgery: When and what?

HOCM: Alcohol ablation or LVOT Surgery: When and what? HOCM: Alcohol ablation or LVOT Surgery: When and what? Paul R Vogt/ Pascal A. Berdat Cardiovascular Center Zurich Clinic Im Park Zurich SKG/SGHC Annual Meeting, Zurich, 10.-12.6.15 ASA/Myectomy: Common

More information

LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION

LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION Jamilah S AlRahimi Assistant Professor, KSU-HS Consultant Noninvasive Cardiology KFCC, MNGHA-WR Introduction LV function assessment in Heart Failure:

More information

HFpEF. April 26, 2018

HFpEF. April 26, 2018 HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes

More information

Summary. Introduction

Summary. Introduction J Biomed Clin Res Volume 8 Number 2, 2015 Review Review ALCOHOL SEPTAL ABLATION Desislava P. Petrova, Sotir T. Marchev, Boyko D. Kuzmanov Specialized Hospital for Active Treatment in Cardiology, Pleven

More information

Restrictive Cardiomyopathy

Restrictive Cardiomyopathy ESC Congress 2011, Paris Imaging Unusual Causes of Cardiomyopathy Restrictive Cardiomyopathy Kazuaki Tanabe, MD, PhD Professor of Medicine Chair, Division of Cardiology Izumo, Japan I Have No Disclosures

More information

Utility of Two-Dimensional and Doppler Echocardiography in Dual-Chamber Pacing for the Cardiomyopathies

Utility of Two-Dimensional and Doppler Echocardiography in Dual-Chamber Pacing for the Cardiomyopathies Arq Bras Cardiol Conferência Nishimura e col Utility of Two-Dimensional and Doppler Echocardiography in Dual-Chamber Pacing for the Cardiomyopathies Rick Nishimura, John Symanski, David Hurrell, A. Jamil

More information

L Faber, A Meissner, P Ziemssen, H Seggewiss

L Faber, A Meissner, P Ziemssen, H Seggewiss 326 Heart 2000;83:326 331 Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients L Faber, A Meissner, P

More information

Systolic Anterior Motion of Mitral Valve Subchordal Apparatus: A Rare Echocardiographic Pattern in Non- Obstructive Hypertrophic Cardiomyopathy

Systolic Anterior Motion of Mitral Valve Subchordal Apparatus: A Rare Echocardiographic Pattern in Non- Obstructive Hypertrophic Cardiomyopathy Case Report Cardiol Res. 2017;8(5):258-264 Systolic Anterior Motion of Mitral Valve Subchordal Apparatus: A Rare Echocardiographic Pattern in Non- Obstructive Hypertrophic Cardiomyopathy Jezreel L. Taquiso

More information

PROSTHETIC VALVE BOARD REVIEW

PROSTHETIC VALVE BOARD REVIEW PROSTHETIC VALVE BOARD REVIEW The correct answer D This two chamber view shows a porcine mitral prosthesis with the typical appearance of the struts although the leaflets are not well seen. The valve

More information

Noninvasive assessment of left ventricular (LV)

Noninvasive assessment of left ventricular (LV) Comparative Value of Tissue Doppler Imaging and M-Mode Color Doppler Mitral Flow Propagation Velocity for the Evaluation of Left Ventricular Filling Pressure* Michal Kidawa, MD; Lisa Coignard, MD; Gérard

More information

The Patient with Atrial Fibrilation

The Patient with Atrial Fibrilation Assessment of Diastolic Function The Patient with Atrial Fibrilation Assoc. Prof. Adriana Ilieşiu, FESC University of Medicine Carol Davila Bucharest, Romania Associated Conditions with Atrial Fibrillation

More information

Prior Authorization Review Panel MCO Policy Submission

Prior Authorization Review Panel MCO Policy Submission Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.

More information

Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy Hypertrophic Cardiomyopathy From Genetics to ECHO Alexandra A Frogoudaki Second Cardiology Department ATTIKON University Hospital Athens University Athens, Greece EUROECHO 2010, Copenhagen, 11/12/2010

More information

Anaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO)

Anaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO) Anaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO) Dr. Siân Jaggar Consultant Anaesthetist Royal Brompton Hospital London UK Congenital Cardiac Services

More information

LV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital

LV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital LV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital LV inflow across MV LV LV outflow across AV LV LV geometric changes Pressure overload

More information

Adult Echocardiography Examination Content Outline

Adult Echocardiography Examination Content Outline Adult Echocardiography Examination Content Outline (Outline Summary) # Domain Subdomain Percentage 1 2 3 4 5 Anatomy and Physiology Pathology Clinical Care and Safety Measurement Techniques, Maneuvers,

More information

Effect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin

Effect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin Effect of Ventricular Pacing on Myocardial Function Inha University Hospital Sung-Hee Shin Contents 1. The effect of right ventricular apical pacing 2. Strategies for physiologically optimal ventricular

More information

Uncommon Doppler Echocardiographic Findings of Severe Pulmonic Insufficiency

Uncommon Doppler Echocardiographic Findings of Severe Pulmonic Insufficiency Uncommon Doppler Echocardiographic Findings of Severe Pulmonic Insufficiency Rahul R. Jhaveri, MD, Muhamed Saric, MD, PhD, FASE, and Itzhak Kronzon, MD, FASE, New York, New York Background: Two-dimensional

More information

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy Developed in Collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography,

More information

Hypertrophic Cardiomyopathy: beyond gradient and wall thickness

Hypertrophic Cardiomyopathy: beyond gradient and wall thickness Hypertrophic Cardiomyopathy: beyond gradient and wall thickness Michael H. Picard, M.D. Massachusetts General Hospital Harvard Medical School no disclosures special thanks to A. Baggish 1 Hypertrophic

More information

Diastolic Heart Failure

Diastolic Heart Failure Diastolic Heart Failure Presented by: Robert Roberts, M.D., FRCPC, MACC, FAHA, FRSC Professor of Medicine and Chair ISCTR University of Arizona, College of Medicine Phoenix Scientist Emeritus and Advisor,

More information

P atients with hypertrophic cardiomyopathy and an outflow

P atients with hypertrophic cardiomyopathy and an outflow 638 CARDIOVASCULAR MEDICINE Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients F H Gietzen,

More information

Diastolic Function Assessment New Guideline Update Practical Approach

Diastolic Function Assessment New Guideline Update Practical Approach Mayo Clinic Department of Cardiovascular Diseases Mayo Clinic Echocardiography Review Course for Boards and Recertification Diastolic Function Assessment New Guideline Update Practical Approach Jae K.

More information

HYPERTROPHY: Behind the curtain. V. Yotova St. Radboud Medical University Center, Nijmegen

HYPERTROPHY: Behind the curtain. V. Yotova St. Radboud Medical University Center, Nijmegen HYPERTROPHY: Behind the curtain V. Yotova St. Radboud Medical University Center, Nijmegen Disclosure of interest: none Relative wall thickness (cm) M 0.22 0.42 0.43 0.47 0.48 0.52 0.53 F 0.24 0.42 0.43

More information

Role of CMR in heart failure and cardiomyopathy

Role of CMR in heart failure and cardiomyopathy Role of CMR in heart failure and cardiomyopathy Hajime Sakuma Department of Radiology, Mie University Late gadolinium enhancement (LGE) LGE MRI can demonstrate site of necrosis, fibrosis or deposition

More information

Effect of Heart Rate on Tissue Doppler Measures of E/E

Effect of Heart Rate on Tissue Doppler Measures of E/E Cardiology Department of Bangkok Metropolitan Administration Medical College and Vajira Hospital, Bangkok, Thailand Abstract Background: Our aim was to study the independent effect of heart rate (HR) on

More information

Cardiac hypertrophy : differentiating disease from athlete

Cardiac hypertrophy : differentiating disease from athlete Cardiac hypertrophy : differentiating disease from athlete Ario Soeryo Kuncoro, MD, Cardiologist Echocardiography Division, National Cardiovascular Centre Harapan Kita-Jakarta Departement of Cardiology

More information

Basic Approach to the Echocardiographic Evaluation of Ventricular Diastolic Function

Basic Approach to the Echocardiographic Evaluation of Ventricular Diastolic Function Basic Approach to the Echocardiographic Evaluation of Ventricular Diastolic Function J A F E R A L I, M D U N I V E R S I T Y H O S P I T A L S C A S E M E D I C A L C E N T E R S T A F F C A R D I O T

More information

Little is known about the degree and time course of

Little is known about the degree and time course of Differential Changes in Regional Right Ventricular Function Before and After a Bilateral Lung Transplantation: An Ultrasonic Strain and Strain Rate Study Virginija Dambrauskaite, MD, Lieven Herbots, MD,

More information

Treatment of Hypertrophic Cardiomyopathy in Bruce B. Reid, MD

Treatment of Hypertrophic Cardiomyopathy in Bruce B. Reid, MD Treatment of Hypertrophic Cardiomyopathy in 2017 Bruce B. Reid, MD Disclosures I have no conflicts of interest to disclose I will not be discussing any off label medications and/or devices Objectives 1)

More information

Cardiac Issues in the Adolescent Athlete. Sean Levchuck, M.D. St. Francis Hospital- The Heart Center

Cardiac Issues in the Adolescent Athlete. Sean Levchuck, M.D. St. Francis Hospital- The Heart Center Cardiac Issues in the Adolescent Athlete Sean Levchuck, M.D. St. Francis Hospital- The Heart Center Sudden Cardiac Death Incidence is.6-6.2 % per 100,000 children in the US 20-25 % of the deaths occur

More information

Cardiac hypertrophy and how it may break an athlete s heart e the Cypriot case

Cardiac hypertrophy and how it may break an athlete s heart e the Cypriot case Eur J Echocardiography (2005) 6, 301e307 Cardiac hypertrophy and how it may break an athlete s heart e the Cypriot case C.E. Chee a,1, C.P. Anastassiades a,1, A.G. Antonopoulos b, A.A. Petsas b, L.C. Anastassiades

More information

Hypertrophic Cardiomyopathy: basics and management

Hypertrophic Cardiomyopathy: basics and management Hypertrophic Cardiomyopathy: basics and management Bette Kim, MD Program Director, Cardiomyopathy Program Director, Roosevelt Hospital Echocardiography Lab Assistant Professor of Clinical Medicine Mount

More information

Updated Meta-Analysis of Septal Alcohol Ablation Versus Myectomy for Hypertrophic Cardiomyopathy

Updated Meta-Analysis of Septal Alcohol Ablation Versus Myectomy for Hypertrophic Cardiomyopathy Journal of the American College of Cardiology Vol. 55, No. 8, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.09.047

More information

Chamber Quantitation Guidelines: What is New?

Chamber Quantitation Guidelines: What is New? Chamber Quantitation Guidelines: What is New? Roberto M Lang, MD J AM Soc Echocardiogr 2005; 18:1440-1463 1 Approximately 10,000 citations iase in itune Cardiac Chamber Quantification: What is New? Database

More information

Objectives. Diastology: What the Radiologist Needs to Know. LV Diastolic Function: Introduction. LV Diastolic Function: Introduction

Objectives. Diastology: What the Radiologist Needs to Know. LV Diastolic Function: Introduction. LV Diastolic Function: Introduction Objectives Diastology: What the Radiologist Needs to Know. Jacobo Kirsch, MD Cardiopulmonary Imaging, Section Head Division of Radiology Cleveland Clinic Florida Weston, FL To review the physiology and

More information

Left ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy

Left ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy Left ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy Bogdan A. Popescu University of Medicine and Pharmacy Bucharest, Romania My conflicts of interest: I have

More information

Coincidence of bicuspid aortic valve presence and hypertrophic cardiomyopathy, and significance of magnetic resonance in its diagnostics

Coincidence of bicuspid aortic valve presence and hypertrophic cardiomyopathy, and significance of magnetic resonance in its diagnostics cor et vasa 55 (2013) e271 e276 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/crvasa Case Report Coincidence of bicuspid aortic valve presence and hypertrophic cardiomyopathy,

More information

Elevated LV filling pressure is a major determinant of cardiac symptoms and

Elevated LV filling pressure is a major determinant of cardiac symptoms and LEFT VENTRICULAR FILLING PRESSURE, DIASTOLIC FUNCTION, AND HEART RATE PATRIZIO LANCELLOTTI, MD, PhD, FESC PERSPECTIVES Author affiliations: University of Liège hospital, GIGA Cardiovascular Science, Heart

More information

National Imaging Associates, Inc. Clinical guidelines CARDIAC CATHETERIZATION -LEFT HEART CATHETERIZATION. Original Date: October 2015 Page 1 of 5

National Imaging Associates, Inc. Clinical guidelines CARDIAC CATHETERIZATION -LEFT HEART CATHETERIZATION. Original Date: October 2015 Page 1 of 5 National Imaging Associates, Inc. Clinical guidelines CARDIAC CATHETERIZATION -LEFT HEART CATHETERIZATION CPT Codes: 93451, 93452, 93453, 93454, 93455, 93456, 93457, 93458, 93459, 93460, 93461 LCD ID Number:

More information

Time Constants of Cardiac Function and Their Calculations

Time Constants of Cardiac Function and Their Calculations 168 The Open Cardiovascular Medicine Journal, 2010, 4, 168-172 Time Constants of Cardiac Function and Their Calculations Open Access Xufang Bai 1, * and Quan Wang 2 1 University of Ottawa Heart Institute,

More information

Diastology Disclosures: None. Dias2011:1

Diastology Disclosures: None. Dias2011:1 Diastology 2011 James D. Thomas, M.D., F.A.C.C. Cardiovascular Imaging Center Department of Cardiology Cleveland Clinic Foundation Cleveland, Ohio, USA Disclosures: None Dias2011:1 Is EVERYBODY a member!?!

More information

Cardiomyopathy: The Good, the Bad.and the Insurable?

Cardiomyopathy: The Good, the Bad.and the Insurable? Cardiomyopathy: The Good, the Bad.and the Insurable? WAHLU Spring Seminar 2014 Joy Geiger, RN, BSN, ALMI Medical Consultant The Northwestern Mutual Life Insurance Company Milwaukee, WI Objectives Overview

More information

Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome

Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome G. Deswarte, AS. Polge, N. Lamblin, A. Millaire, M. Richardson, C. Bauters,

More information

Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert

Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert University of Groningen Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you

More information

Apical Hypertrophic Cardiomyopathy With Hemodynamically Unstable Ventricular Arrhythmia Atypical Presentation

Apical Hypertrophic Cardiomyopathy With Hemodynamically Unstable Ventricular Arrhythmia Atypical Presentation Cronicon OPEN ACCESS Hemant Chaturvedi* Department of Cardiology, Non-Invasive Cardiology, Eternal Heart Care Center & research Institute, Rajasthan, India Received: September 15, 2015; Published: October

More information

Articles in PresS. J Appl Physiol (September 29, 2005). doi: /japplphysiol

Articles in PresS. J Appl Physiol (September 29, 2005). doi: /japplphysiol Articles in PresS. J Appl Physiol (September 29, 2005). doi:10.1152/japplphysiol.00671.2005 Assessment of Left Ventricular Diastolic Function by Early Diastolic Mitral Annulus Peak Acceleration Rate: Experimental

More information

Appendix II: ECHOCARDIOGRAPHY ANALYSIS

Appendix II: ECHOCARDIOGRAPHY ANALYSIS Appendix II: ECHOCARDIOGRAPHY ANALYSIS Two-Dimensional (2D) imaging was performed using the Vivid 7 Advantage cardiovascular ultrasound system (GE Medical Systems, Milwaukee) with a frame rate of 400 frames

More information

Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition

Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac

More information

Left Ventricular End-Diastolic Pressure in Evaluating Left Ventricular Function

Left Ventricular End-Diastolic Pressure in Evaluating Left Ventricular Function Clin. Cardiol. 4,28-33 (1981) 0 G. Witzstrock Publishing House, nc. Practitioner s Corner Left Ventricular End-Diastolic Pressure in Evaluating Left Ventricular Function A. s. SKANDRAN, M.D., B. L. SEGAL,

More information

WHAT DO ELECTROPHYSIOLOGISTS WANT TO KNOW FROM ECHOCARDIOGRAPHERS BEFORE, DURING&AFTER CARDIAC RESYNCHRONIZATION THERAPY?

WHAT DO ELECTROPHYSIOLOGISTS WANT TO KNOW FROM ECHOCARDIOGRAPHERS BEFORE, DURING&AFTER CARDIAC RESYNCHRONIZATION THERAPY? WHAT DO ELECTROPHYSIOLOGISTS WANT TO KNOW FROM ECHOCARDIOGRAPHERS BEFORE, DURING&AFTER CARDIAC RESYNCHRONIZATION THERAPY? Mary Ong Go, MD, FPCP, FPCC, FACC OUTLINE What is CRT Who needs CRT What does the

More information

ESC Guidelines on Hypertrophic Cardiomyopathy

ESC Guidelines on Hypertrophic Cardiomyopathy 2014 version ES Guidelines on Hypertrophic ardiomyopathy Pr Michel KOMAJDA Dept of ardiology HU PTE SALPETRERE University Pierre et Marie urie PARS FRANE European Heart Journal (2014):doi:10.1093/eurheartj/ehu284

More information

Left Atrial Deformation Predicts Pulmonary Capillary Wedge Pressure in Pediatric Heart Transplant Recipients

Left Atrial Deformation Predicts Pulmonary Capillary Wedge Pressure in Pediatric Heart Transplant Recipients DOI: 10.1111/echo.12679 2014, Wiley Periodicals, Inc. Echocardiography Left Atrial Deformation Predicts Pulmonary Capillary Wedge Pressure in Pediatric Heart Transplant Recipients Jay Yeh, M.D.,* Ranjit

More information